J Nutr

Vitamin D shows no short‑term impact on COVID‑19 outcomes

March 13, 2026

The randomized, double‑blind VIVID trial (NCT04536298) of 1,747 adults with newly diagnosed COVID‑19 found that high‑dose vitamin D₃ did not significantly change 4‑week healthcare utilization, disease severity, or other clinical outcomes compared with placebo. Rates of hospitalization or other healthcare visits were similar between groups (28% vs. 29%). Secondary outcomes, including prevention of infection in household contacts, also showed no meaningful differences. Per‑protocol analyses suggested a nonsignificant trend toward lower long COVID prevalence at 8 weeks, warranting further study.

Clinical takeaway: Continue to base COVID‑19 management on established evidence-based therapies; vitamin D supplementation alone should not be expected to modify short‑term clinical outcomes.

Source:

Ganmaa D, et al. (2026, March 12). J Nutr. A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial. https://www.sciencedirect.com/science/article/abs/pii/S0022316626000477